MCID: PST022
MIFTS: 45

Posterior Uveal Melanoma

Categories: Cancer diseases, Eye diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Posterior Uveal Melanoma

MalaCards integrated aliases for Posterior Uveal Melanoma:

Name: Posterior Uveal Melanoma 12 15
Ciliary Body and Choroid Melanoma, Medium/large Size 74
Ciliary Body and Choroid Melanoma, Small Size 74
Medium/large Size Posterior Uveal Melanoma 12
Small Size Posterior Uveal Melanoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6566
NCIt 51 C9089 C9090

Summaries for Posterior Uveal Melanoma

MalaCards based summary : Posterior Uveal Melanoma, also known as ciliary body and choroid melanoma, medium/large size, is related to melanoma, uveal and melanoma. An important gene associated with Posterior Uveal Melanoma is THBS2 (Thrombospondin 2), and among its related pathways/superpathways are Pathways in cancer and PI3K-Akt signaling pathway. The drugs Melphalan and Fotemustine have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and bone, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Posterior Uveal Melanoma

Diseases in the Melanoma, Uveal family:

Melanoma, Uveal 1 Melanoma, Uveal 2
Posterior Uveal Melanoma

Diseases related to Posterior Uveal Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
# Related Disease Score Top Affiliating Genes
1 melanoma, uveal 11.0
2 melanoma 11.0
3 kashin-beck disease 10.0 BCL2 VEGFA
4 soft tissue sarcoma 10.0 BCL2 VEGFA
5 retinal detachment 10.0
6 retinoblastoma 10.0
7 microphthalmia 10.0
8 gastric lymphoma 10.0 BCL2 VEGFA
9 retinal ischemia 9.9 BCL2 VEGFA
10 vascular cancer 9.7 THBS1 VEGFA
11 arteriovenous malformations of the brain 9.7 THBS1 VEGFA
12 differentiated thyroid carcinoma 9.7 BCL2 VEGFA
13 corneal neovascularization 9.7 THBS1 VEGFA
14 glioma 9.6 BCL2 CCND2 VEGFA

Graphical network of the top 20 diseases related to Posterior Uveal Melanoma:



Diseases related to Posterior Uveal Melanoma

Symptoms & Phenotypes for Posterior Uveal Melanoma

MGI Mouse Phenotypes related to Posterior Uveal Melanoma:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.95 BCL2 CCND2 MITF THBS1 THBS2 VEGFA
2 homeostasis/metabolism MP:0005376 9.93 BCL2 CCND2 MITF THBS1 THBS2 VEGFA
3 behavior/neurological MP:0005386 9.92 BCL2 CCND2 MITF THBS2 VEGFA
4 cardiovascular system MP:0005385 9.91 BCL2 CCND2 THBS1 THBS2 VEGFA
5 immune system MP:0005387 9.91 BCL2 CCND2 MITF THBS1 THBS2 VEGFA
6 endocrine/exocrine gland MP:0005379 9.89 BCL2 CCND2 MITF THBS1 VEGFA
7 integument MP:0010771 9.8 BCL2 MITF THBS1 THBS2 VEGFA
8 mortality/aging MP:0010768 9.8 BCL2 CCND2 MITF THBS1 THBS2 VEGFA
9 limbs/digits/tail MP:0005371 9.67 MITF THBS1 THBS2 VEGFA
10 muscle MP:0005369 9.56 BCL2 THBS1 THBS2 VEGFA
11 neoplasm MP:0002006 9.46 BCL2 THBS1 THBS2 VEGFA
12 reproductive system MP:0005389 9.35 BCL2 CCND2 MITF THBS1 VEGFA
13 vision/eye MP:0005391 9.02 BCL2 CCND2 MITF THBS1 VEGFA

Drugs & Therapeutics for Posterior Uveal Melanoma

Drugs for Posterior Uveal Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Melphalan Approved Phase 3 148-82-3 460612 4053
2
Fotemustine Experimental, Investigational Phase 3
3 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
4 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
5 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
6 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1
7 Liver Extracts Phase 3,Phase 1,Not Applicable,Early Phase 1
8 Vaccines Phase 3,Phase 2,Phase 1
9
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
10
Bevacizumab Approved, Investigational Phase 2 216974-75-3
11
Sodium Citrate Approved, Investigational Phase 2 68-04-2
12
Cisplatin Approved Phase 2 15663-27-1 441203 84093 2767
13
Sunitinib Approved, Investigational Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
14
Tamoxifen Approved Phase 2 10540-29-1 2733526
15
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
16
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
17
Carboplatin Approved Phase 2 41575-94-4 38904 10339178 498142
18
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
19
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
20
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
21
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
22
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
23
Ipilimumab Approved Phase 2,Phase 1,Early Phase 1 477202-00-9
24
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
25
Aluminum sulfate Approved Phase 2 10043-01-3
26
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
27
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
28
Iodine Approved, Investigational Phase 2,Phase 1 7553-56-2 807
29
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
30
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
31
Acetaminophen Approved Phase 2 103-90-2 1983
32
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
33
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
34
Promethazine Approved, Investigational Phase 2 60-87-7 4927
35
Lenalidomide Approved Phase 2 191732-72-6 216326
36
Cyclophosphamide Approved, Investigational Phase 2,Early Phase 1 6055-19-2, 50-18-0 2907
37
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
38
Imidazole Experimental, Investigational Phase 2 288-32-4 795
39
SB-649868 Experimental, Investigational Phase 2 110-16-7, 110-17-8 444972
40
Cediranib Investigational Phase 2 288383-20-0 9933475
41 Antineoplastic Agents, Immunological Phase 2,Phase 1,Early Phase 1
42 Angiogenesis Modulating Agents Phase 2,Phase 1
43 Angiogenesis Inhibitors Phase 2,Phase 1
44 Bone Density Conservation Agents Phase 2
45 Protein Kinase Inhibitors Phase 2,Phase 1
46 Estrogen Receptor Antagonists Phase 2
47 Estrogen Antagonists Phase 2
48 Hormones Phase 2,Phase 1
49 Citrate Phase 2
50 Antineoplastic Agents, Hormonal Phase 2

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
2 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
3 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
4 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
5 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
6 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
7 Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance Completed NCT01100528 Phase 2 dacarbazine
8 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
9 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
10 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2 nab-paclitaxel
11 Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma Completed NCT00288041 Phase 2 carboplatin;paclitaxel;bortezomib
12 VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00450255 Phase 2
13 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Completed NCT00121225 Phase 2 vorinostat
14 Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma Completed NCT00089063 Phase 2 Montanide ISA 51 VG
15 Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Completed NCT00085189 Phase 2 Montanide ISA 51 VG;agatolimod sodium
16 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma Completed NCT00243061 Phase 2 cediranib maleate
17 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
18 PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT00238329 Phase 2 thalidomide
19 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Completed NCT00085306 Phase 2
20 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
21 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
22 Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
23 Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma Completed NCT00031733 Phase 2 alum adjuvant
24 Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00005815 Phase 1, Phase 2 temozolomide;thalidomide
25 Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Completed NCT00089219 Phase 1, Phase 2
26 Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
27 Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00058279 Phase 1, Phase 2
28 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Completed NCT00089206 Phase 2
29 Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma Recruiting NCT02068586 Phase 2 Sunitinib;Valproic Acid
30 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
31 Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma Terminated NCT00482911 Phase 2 cyclophosphamide;lenalidomide;sunitinib malate
32 Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00471471 Phase 1
33 Dendritic Cell Vaccination During Lymphoid Reconstruction Completed NCT00313508 Phase 1 Fludarabine
34 Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma Completed NCT01005472 Phase 1 sunitinib malate;temozolomide
35 Vaccine Therapy in Treating Patients With Advanced Melanoma Completed NCT00705640 Phase 1
36 Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery Completed NCT00025181 Phase 1
37 Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Completed NCT00398073 Phase 1
38 Vaccine Therapy in Treating Patients With Metastatic Cancer Completed NCT00020267 Phase 1 interleukin-2;MAGE-12 peptide vaccine;Montanide ISA-51
39 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
40 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
41 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Terminated NCT00005841 Phase 1
42 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
43 Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma Completed NCT00897624
44 Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye Completed NCT00952939
45 Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases Terminated NCT02336763 Not Applicable
46 Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases Terminated NCT01730157 Early Phase 1
47 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Terminated NCT00499733 Early Phase 1 cyclophosphamide
48 Validation of a Molecular Prognostic Test for Eye Melanoma Withdrawn NCT00406120

Search NIH Clinical Center for Posterior Uveal Melanoma

Genetic Tests for Posterior Uveal Melanoma

Anatomical Context for Posterior Uveal Melanoma

MalaCards organs/tissues related to Posterior Uveal Melanoma:

42
Eye, Liver, Bone, Testes, Endothelial, Skin, Bone Marrow

Publications for Posterior Uveal Melanoma

Articles related to Posterior Uveal Melanoma:

(show top 50) (show all 95)
# Title Authors Year
1
Plaque brachytherapy for posterior uveal melanoma in 2018: improved techniques and expanded indications. ( 29538180 )
2018
2
Unsuspected and misdiagnosed posterior uveal melanoma following enucleation and evisceration in Ottawa-Gatineau. ( 29631828 )
2018
3
Long-Term Metastatic Risk after Biopsy of Posterior Uveal Melanoma. ( 29705056 )
2018
4
Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses. ( 29789761 )
2018
5
Posterior uveal melanoma in adolescents and children: current perspectives. ( 30464381 )
2018
6
Clinical Features, Metastasis, and Survival in Patients Younger Than 21 Years With Posterior Uveal Melanoma. ( 30422230 )
2018
7
INTRAVITREAL DEXAMETHASONE (OZURDEX) IMPLANT FOR RADIATION MACULOPATHY SECONDARY TO STEREOTACTIC RADIOTHERAPY FOR POSTERIOR UVEAL MELANOMA. ( 28489707 )
2017
8
Local Failure After Episcleral Brachytherapy for Posterior Uveal Melanoma: Patterns, Risk Factors, and Management. ( 28163118 )
2017
9
Local Failure After Episcleral Brachytherapy for Posterior Uveal Melanoma: Patterns, Risk Factors, and Management. ( 28756956 )
2017
10
Repeat Episcleral Plaque Brachytherapy: Clinical Outcomes in Patients Treated for Locally Recurrent Posterior Uveal Melanoma. ( 28048976 )
2016
11
Clinical application of genetic testing for posterior uveal melanoma. ( 27847622 )
2016
12
Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture. ( 25439609 )
2015
13
Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications. ( 24270974 )
2014
14
Relationship between rate of posterior uveal melanoma flattening following plaque radiotherapy and GEP class of tumor cells. ( 24408979 )
2014
15
Treatment of posterior uveal melanoma with multi-dose photodynamic therapy. ( 24463441 )
2014
16
Diffusion restriction of posterior uveal melanoma on MR imaging. ( 25597216 )
2014
17
Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma. ( 22944897 )
2013
18
Long-term followup comparing two treatment dosing strategies of (125) I plaque radiotherapy in the management of small/medium posterior uveal melanoma. ( 23533708 )
2013
19
American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. ( 23664467 )
2013
20
Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. ( 24169649 )
2013
21
Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma. ( 22995029 )
2013
22
Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma. ( 24092966 )
2013
23
Tumor-related lipid exudation and associated tumor-related complications after plaque radiotherapy of posterior uveal melanoma. ( 23483500 )
2013
24
Posterior uveal melanoma coexistent with macular hole. ( 23604299 )
2013
25
One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma. ( 21534252 )
2012
26
Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review. ( 22536035 )
2012
27
Safety of pars plana vitrectomy in eyes with plaque-irradiated posterior uveal melanoma. ( 23044941 )
2012
28
Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. ( 22848417 )
2012
29
Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers. ( 22039239 )
2011
30
Posterior uveal melanoma in young patients treated with proton beam therapy. ( 20224468 )
2010
31
No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma. ( 20429631 )
2010
32
Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. ( 19644367 )
2009
33
A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. ( 19876071 )
2009
34
The T1799A point mutation is present in posterior uveal melanoma. ( 18985043 )
2008
35
Posterior uveal melanoma. Distribution of the sites of origin and patterns of tumour extent in the ocular fundus. ( 18523080 )
2008
36
Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation. ( 17585309 )
2008
37
In vivo monosomy 3 detection of posterior uveal melanoma: 3-year follow-up. ( 17934749 )
2008
38
Lipid exudation following plaque radiotherapy for posterior uveal melanoma. ( 16490526 )
2006
39
Apoptosis inhibitor, survivin, in posterior uveal melanoma: comparison among primary tumors, tumors resistant to brachytherapy, tumors with liver metastases, and liver metastases. ( 16531282 )
2006
40
Proton or stereotactic photon irradiation for posterior uveal melanoma? A planning intercomparison. ( 16362788 )
2005
41
18 years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma. ( 16170122 )
2005
42
Genomic investigations of posterior uveal melanoma. ( 16352494 )
2005
43
Differential expression of angioregulatory matricellular proteins in posterior uveal melanoma. ( 16314734 )
2005
44
Association between posterior uveal melanoma and iris freckles, iris naevi, and choroidal naevi. ( 14693769 )
2004
45
Association between choroidal pigmentation and posterior uveal melanoma in a white population. ( 14693770 )
2004
46
Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma. ( 15205232 )
2004
47
Pars plana vitrectomy in eyes containing a treated posterior uveal melanoma. ( 12967800 )
2003
48
Noncontiguous tumor recurrence of posterior uveal melanoma after transscleral local resection. ( 12470139 )
2002
49
Management of posterior uveal melanoma: past, present, future. ( 11927844 )
2002
50
Changes in ultrasound findings in posterior uveal melanoma after Ruthenium 106 brachytherapy. ( 12045056 )
2002

Variations for Posterior Uveal Melanoma

Expression for Posterior Uveal Melanoma

Search GEO for disease gene expression data for Posterior Uveal Melanoma.

Pathways for Posterior Uveal Melanoma

Pathways related to Posterior Uveal Melanoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1 12.35 BCL2 CCND2 MITF VEGFA
2
Show member pathways
12.19 BCL2 CCND2 THBS1 THBS2 VEGFA
3
Show member pathways
12.15 BCL2 CCND2 MITF VEGFA
4 11.93 BCL2 CCND2 THBS1 VEGFA
5
Show member pathways
11.91 BCL2 CCND2 THBS1
6
Show member pathways
11.79 BCL2 CCND2 THBS1 THBS2 VEGFA
7 11.58 BCL2 THBS1
8 11.55 BCL2 VEGFA
9 11.54 BCL2 VEGFA
10 11.42 CCND2 MITF
11
Show member pathways
11.39 THBS1 THBS2
12 11.36 THBS1 VEGFA
13
Show member pathways
11.3 BCL2 CCND2
14 11.15 THBS1 THBS2
15 11.07 THBS1 THBS2
16 11.02 BCL2 MITF

GO Terms for Posterior Uveal Melanoma

Cellular components related to Posterior Uveal Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 9.26 THBS1 VEGFA
2 platelet alpha granule lumen GO:0031093 9.16 THBS1 VEGFA
3 extracellular matrix GO:0031012 9.13 THBS1 THBS2 VEGFA
4 platelet alpha granule GO:0031091 8.62 THBS1 THBS2

Biological processes related to Posterior Uveal Melanoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.49 BCL2 VEGFA
2 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.48 THBS1 VEGFA
3 humoral immune response GO:0006959 9.46 BCL2 MITF
4 positive regulation of endothelial cell migration GO:0010595 9.43 THBS1 VEGFA
5 positive regulation of blood vessel endothelial cell migration GO:0043536 9.4 THBS1 VEGFA
6 ovarian follicle development GO:0001541 9.37 BCL2 VEGFA
7 pigmentation GO:0043473 9.32 BCL2 MITF
8 sprouting angiogenesis GO:0002040 9.26 THBS1 VEGFA
9 positive regulation of cell proliferation GO:0008284 9.26 BCL2 CCND2 THBS1 VEGFA
10 melanocyte differentiation GO:0030318 9.16 BCL2 MITF
11 negative regulation of apoptotic process GO:0043066 9.02 BCL2 CCND2 MITF THBS1 VEGFA

Molecular functions related to Posterior Uveal Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix binding GO:0050840 9.16 THBS1 VEGFA
2 fibronectin binding GO:0001968 8.96 THBS1 VEGFA
3 heparin binding GO:0008201 8.8 THBS1 THBS2 VEGFA

Sources for Posterior Uveal Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....